Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42

Benzinga Newsdesk www.benzinga.com Negative 61.1%

Neg 61.1% Neu 0% Pos 0%

Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and lowers the price target from $45 to $42.